The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Open accessAbstract
The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes allowed the detection of in vivo–produced IL-1β. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1β in healthy subjects. In contrast, patients with cryopyrin-associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with canakinumab not only induced long-lasting complete clinical response but also reduced the production rate of IL-1β to normal levels within 8 wk of treatment, suggesting that IL-1β production in these patients was mainly IL-1β driven. The model further indicated that IL-1β is the only cytokine driving disease severity and duration of response to canakinumab. A correction for natural IL-1 antagonists was not required to fit the data. Together, the study allowed new insights into the production and regulation of IL-1β in man. It also indicated that CAPS is entirely mediated by IL-1β and that canakinumab treatment restores physiological IL-1β production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 1×
“These mutations are supposed to promote release of IL-1, thereby providing an excellent paradigm for studying human IL-1 in vivo (4, 5).”
BackgroundSelf-citationHoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Sutterwala, F. S., Ogura, Y., Szczepanik, M., Lara-Tejero, M., Lichtenberger, G. S., Grant, E. P., Bertin, J., Coyle, A. J., Galán, J. E., Askenase, P. W., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.02.004 · Cited by 980
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Self-citationUse of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Self-citationActive Caspase-1 Is a Regulator of Unconventional Protein Secretion
Keller, M., Rüegg, A., Werner, S., & Beer, H.-D. (2008) · Cell · doi:10.1016/j.cell.2007.12.040 · Cited by 850
Aksentijevich, I., Nowak, M., Mallah, M., Chae, J. J., Watford, W. T., Hofmann, S. R., Stein, L., Russo, R., Goldsmith, D., Dent, P., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10688 · Cited by 709
Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
Hawkins, P. N., Lachmann, H. J., & McDermott, M. F. (2003) · New England Journal of Medicine · doi:10.1056/nejm200306193482523 · Cited by 654
Self-citationThe IL-1 family and inflammatory diseases.
Dinarello, C. A. (2002) · PubMed · Cited by 599
Cited by
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962
Regulation of inflammasome signaling
Rathinam, V. A. K., Vanaja, S. K., & Fitzgerald, K. A. (2012) · Nature Immunology · doi:10.1038/ni.2237 · Cited by 927
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Self-citationTherapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
Chronic Inflammation in Cancer Development
Multhoff, G., Molls, M., & Radons, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00098 · Cited by 576
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells
Arbore, G., West, E. E., Spolski, R., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z. X., O’Neill, L. A., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513
Self-citationThe NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
The NLRP12 Inflammasome Recognizes Yersinia pestis
Vladimer, G. I., Weng, D., Paquette, S. W. M., Vanaja, S. K., Rathinam, V. A. K., Aune, M. H., Conlon, J. E., Burbage, J. J., Proulx, M. K., Liu, Q., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.07.006 · Cited by 366
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Rébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
Role of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
IL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
Functions of NOD-Like Receptors in Human Diseases
Zhong, Y., Kinio, A., & Saleh, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00333 · Cited by 317
So, A., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & Schlesinger, N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27600 · Cited by 315
NLRP1 Inflammasome Activation Induces Pyroptosis of Hematopoietic Progenitor Cells
Masters, S. L., Gerlic, M., Metcalf, D., Preston, S., Pellegrini, M., O’Donnell, J. A., McArthur, K., Baldwin, T. M., Chevrier, S., Nowell, C. J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.027 · Cited by 313
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 295
Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., Dinarello, C. A., & Fujita, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064907 · Cited by 293
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Caspase-1: The inflammasome and beyond
Sollberger, G., Strittmatter, G. E., Garstkiewicz, M., Sand, J., & Beer, H.-D. (2014) · Innate Immunity · doi:10.1177/1753425913484374 · Cited by 275
Dhimolea, E. (2010) · mAbs · doi:10.4161/mabs.2.1.10328 · Cited by 270
Lee, J. W., Kelley, M., King, L. E., Yang, J., Salimi-Moosavi, H., Tang, M. T., Lu, J.-F., Kamerud, J., Ahene, A., Myler, H., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9251-3 · Cited by 270
Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3266 · Cited by 121
Self-citationChen, K., Linares, I. M., Trempel, M. A., Feidler, A. M., De Silva, D., Farajollahi, S., Jones, J., Kuebel, J., Kasap, P., Engelhardt, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202508271 · Cited by 9
Metadata
- Authors
- Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., Hawkins, P. N., & Jung, T.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2009-04-13
- Volume
- 206
- Issue
- 5
- Pages
- 1029-1036
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2110348886
- Cited by
- 312
- References
- 23
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.